Back to news

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

Business Wire•19/11/2026•08:00 ET
1

Key Highlights

  • ➤LUMINA Phase 2 met its primary endpoint, supporting mangaciclanol’s advancement into Phase 3
  • ➤Mangaciclanol and gadobutrol showed similar overall diagnostic preference in blinded comparisons
  • ➤Mangaciclanol dose selected for Phase 3 at 0.1mmol/kg
  • ➤Mangaciclanol was well tolerated, with no safety concerns identified during Phase 2
  • ➤FDA granted mangaciclanol Fast Track designation for potential unmet-need benefits

Expert Statements

Robert J. McDonald, M.D., Ph.D., neuroradiologist at Mayo Clinic and principal investigator of the LUMINA study

“For years, clinicians and patients have asked whether we can achieve the diagnostic confidence of gadolinium without the concerns around tissue retention and nephrogenic systemic fibrosis risk. These Phase 2 results are an important step toward answering that question. Seeing a manganese-based agent perform this well under blinded comparison with an established gadolinium agent is encouraging, and I look forward to what Phase 3 will show across a broader range of patients.”

Kevin O’Neill, President & CEO of Pharmaceutical Diagnostics, GE HealthCare

“These positive Phase 2 results support dose selection for Phase 3, which will further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for detecting and characterizing lesions of the central nervous system and body. As aging populations and the rising burden of chronic disease drive demand for imaging, we continue to invest in our contrast media portfolio and in what comes next. Manganese-based contrast agents have the potential to transform the MRI market, helping meet the evolving needs of clinicians and patients.”

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

* Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in